No association of XRCC1 and CLPTM1L polymorphisms with non-small cell lung cancer in a non-smoking Han Chinese population

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 5171-5174

  Sun, Yan ^a   Zhang, Yong Jun ^a   Kong, Xiang Ming ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Chinese population; CLPTM1L; Never smoker; Single nucleotide polymorphisms; XRCC1

Indexed keywords

CLPTM1L PROTEIN, HUMAN; DNA BINDING PROTEIN; MEMBRANE PROTEIN; TUMOR PROTEIN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADENOCARCINOMA; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CHINA; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHINA; DNA-BINDING PROTEINS; FEMALE; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING;

EID: 84887571451     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.5171     Document Type: Article

References (26)

1. Broderick P, Wang Y, Vijayakrishnan J, et al (2009). Deciphering the impact of common genetic variation on lung cancer risk: A genome-wide association study. Cancer Res, 69, 6633-41.
2. Campalans A, Marsin S, Nakabeppu Y, et al (2005). XRCC1 interactions with multiple DNA glycosylases: a model for its recruitment to base excision repair. DNA Repair (Amst), 4, 826-35.
3. Carbonnelle E, Mesquita C, Bille E, et al (2011). MALDI-TOF mass sepectrometry tools for bacterial identification in clinical microbiology laboratory. Clin Biochem, 44, 104-9.
4. Chang JS, Wrensch MR, Hansen HM, et al (2009). Base excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African-Americans. Carcinogenesis, 30, 78-87.
5. Huang MY, Huang ML, Chen MJ, et al (2011). Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics, 21, 18-25.
6. Hoeijmakers JH (2001). Genome maintenance mechanisms for preventing cancer. Nature, 411, 366-74.
7. Horgan AM, Yang B, Azad AK, et al (2011). Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Onco, 16, 296-304.
8. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2004). Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum, 83, 1-1438.
9. James MA, Wen W, Wang Y, et al (2012). Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus. PLoS One, 7, e36116.
10. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.
11. Kim IS, Lee GW, Kim DC, et al (2010). Polymorphisms and haplotypes in the XRCC1 gene and the risk of advanced non-small cell lung cancer. J Thorac Oncol, 5, 1912-21.
12. Lindahl T, Wood RD (1999). Quality control by DNA repair. Science, 286, 1897-905.
13. Liu P, Vikis HG, Lu Y, et al (2010). Cumulative effect of multiple loci on genetic susceptibility to familial lung cancer. Cancer Epidemiol Biomarkers Prev, 19, 517-24.
14. Mahimkar MB, Samant TA, Kannan S, et al (2012). Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy. Mol Carcinog, 5, E94-103.
15. McKay JD, Hung RJ, Gaborieau V, et al (2008). Lung cancer susceptibility locus at 5p15.33. Nat Genet, 40, 1404-6.
16. Pande M, Spitz MR, Wu X, et al (2011). Novel genetic variants in the chromosome 5p15.33 region associate with lung cancer risk. Carcinogenesis, 32, 1493-9.
17. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
18. Qian J, Massion PP (2008). Role of chromosome 3q amplifification in lung cancer. J Thorac Oncol, 3, 212-5.
19. Rafnar T, Sulem P, Stacey SN, et al (2009). Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet, 41, 221-7.
20. Wang Y, Broderick P, Matakidou A, et al (2010). Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers. Carcinogenesis, 31, 234-8.
21. Wang Y, Broderick P, Webb E, et al (2008). Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet, 40, 1407-9.
22. Weaver DA, Crawford EL, Warner KA, et al (2005). ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer, 4,18.
23. Wu J, Liu J, Zhou Y, et al (2012). Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res, 18, 3972-81.
24. Yamamoto K, Okamoto A, Isonishi S, et al (2001). A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem Biophys Res Commun, 280, 1148-54.
25. Zhu G, Lippard SJ (2009). Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-links. Biochemistry, 48, 4916-25.
26. Zienolddiny S, Skaug V, Landvik NE, et al. (2009). The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adducts formation in the lung. Carcinogenesis, 30, 1368-71.